Sanofi

Sanofi-a Ventis Deutschland Gmbh

Sanofi-aventis

Thyssenkrupp Nucera Ag & Co. Kgaa

Antaros Medical Ab

Michael Wagner

Andreas Evers

Torsten Haack

Siegfried Stengelin

Martin Bossart

Bernd Henkel

Dieter Kadereit

Katrin Lorenz

Martin Lorenz

Herman Schreuder

Christopher Kallus

Armin Bauer

Marc Nazare

Mark Broenstrup

Anja Globisch

Volkmar Wehner

Hans Matter

Ralf Elvert

Pradeep K Dhal

Matthias Urmann

James E Stefano

Thomas Olpp

Nino Meyer

Paul Konowicz

Joachim Brendel

Klaus Wirth

Manfred Schudok

Jean-Marie Ruxer

Anna Kohlmann

Stefania Pfeiffer-Marek

Fabienne Pilorge

Heinrich Englert

Peyman Sakhaii

Nils Poth

Kurt Ritter

David William Will

Stefan Peukert

Oliver Plettenburg

Peter Woltering

Aimo Kannt

Hermut Wehlan

Volker Laux

Peter Toros

Sebastian Austenfeld

Werner Seiz

Robert Miller

Magnus Besev

Romain Bertrand

Maximilian Bielohuby

Stephanie Keil

Heinrich Christian Englert

A textile can be configured as a spacer between a housing or a supporting structure and an electrode or a substructure of an electrode of a zero-gap electrolytic cell. The textile may comprise a mechanical connection means composed of an elastic polymeric material and may comprise an electrical connection means different from the mechanical connection means. A zero-gap electrolytic cell can be furnished with such a textile. Further, a method for producing such a zero-gap electrolytic cell may be characterized in that at least one ply of a textile is placed into an anode tank or cathode tank, an anode or cathode electrode is disposed on the at least one ply of the textile, an ion exchange membrane is placed onto this electrode, and a cathode electrode or anode electrode connected to a cathode tank or anode tank, respectively, is disposed on the ion exchange membrane.

Use of a textile, zero-gap electrolytic cell and production method therefor

The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.

GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L-L-L-L-Y&#x2014;Rgroups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon receptor agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising the conjugate or the pharmaceutically acceptable salt thereof as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon receptor agonist.

Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid

The present invention relates to exendin-4 peptide analogues which selectively bind and activate the glucagon receptor and comprise a chelating moiety capable of binding a metal ion and their use, for example in PET imaging.

Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes

The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon agonist linker conjugate Z-L-L-L-Y&#x2014;R, wherein Y represents an GLP-1/Glucagon agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), wherein the dashed line indicates the attachment to one of the amino groups of the GLP-1/Glucagon agonist moiety by forming an amide bond. The invention further relates to pharmaceutical compositions comprising said prodrugs as well as their use as a medicament for treating or preventing diseases or disorders which can be treated by GLP-1/Glucagon agonist. 

Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate

The present invention relates to a conjugate or a pharmaceutically acceptable salt thereof comprising an GLP-1/Glucagon receptor agonist, a linker and a hyaluronic acid hydrogel bearing -L1-L2-L-Y&#x2014;R20 groups, wherein Y represents an GLP-1/Glucagon receptor agonist moiety; and -L is a linker moiety&#x2014;by formula (Ia), 

Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

Exendin-4 derivatives as dual GLP1/glucagon agonists

The present invention relates to trigonal GLP-1/glucagon/GIP receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists

Compounds as peptidic GLP1/glucagon/GIP receptor agonists

Functionalized Exendin-4 derivatives

The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.

Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

The present invention relates to glucagon receptor agonists and their medical use, for example in the treatment of severe hypoglycemia.

Exendin-4 derivatives as selective glucagon receptor agonists

The present invention relates to macrocydic urea derivatives of the formula I (I) in which R1, R2, R3, V and Y are as defined below. The compounds of the formula I are inhibitors of the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor). The invention further relates to the process for the preparation of the compounds of formula I and to the use thereof as medicaments. 

Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals

Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists

Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists

Growing community of inventors

Frankfurt am Main, Germany

Michael Wagner